Shirahama T, Cohen A S
J Exp Med. 1974 Oct 1;140(4):1102-7. doi: 10.1084/jem.140.4.1102.
Colchicine was found to have a strong inhibitory effect on amyloid induction in an animal model. When CBA/J mice were treated with colchicine concurrently with the amyloid induction regimen, the incidence of amyloidosis was, depending upon the dosage of colchicine, significantly decreased (0.005-0.010 mg colchicine per day) or completely blocked (more than 0.015 mg colchicine per day). The colchicine treatment was effective not only when colchicine was given for the entire course of the amyloid induction regimen but also when it was given only in the late pre-amyloid or the amyloid phase of the regimen or to the recipients after the transfer of amyloid. The data suggest the colchicine is effective in blocking amyloidogenesis at its final stage(s), while it may not affect significantly amyloid already deposited in the tissue.
秋水仙碱在动物模型中被发现对淀粉样蛋白诱导具有强烈的抑制作用。当CBA/J小鼠在淀粉样蛋白诱导方案的同时接受秋水仙碱治疗时,根据秋水仙碱的剂量,淀粉样变性的发生率显著降低(每天0.005 - 0.010毫克秋水仙碱)或完全阻断(每天超过0.015毫克秋水仙碱)。秋水仙碱治疗不仅在淀粉样蛋白诱导方案的整个过程中给予时有效,而且在方案的淀粉样蛋白前期晚期或淀粉样蛋白期仅给予时,或在淀粉样蛋白转移后给予受体时也有效。数据表明秋水仙碱在其最后阶段有效地阻断淀粉样蛋白生成,而它可能不会显著影响已经沉积在组织中的淀粉样蛋白。